March 9, 2017
Once dubbed a “death panel”, the Independent Payment Advisory Board is back in the news. The board was devised under the Affordable Care Act as a cost-cutting entity that will materialize once Medicare spending exceeds a specified growth rate.
March 7, 2017
Two new publications point to the value of treating hepatitis C – early, aggressively and alongside heightened screening efforts.
March 2, 2017
New pain treatment guidelines underscore a now familiar disconnect: the gap between what patients need and what their health plans will pay for.
February 28, 2017
Rare Disease Day brings international attention to the plight of patients who struggle with ALS, Gaucher disease, cystic fibrosis and other less common conditions. This year’s theme is research, a challenge for any disease state but especially for conditions with small patient populations.
February 24, 2017
The Institute for Clinical and Economic Review has issued a draft report concluding that targeted immune modulators, such as biologic treatments, for rheumatoid arthritis are too expensive. The conclusion could embolden health plans to limit patient access.
But does ICER’s model accurately reflect the experiences of the 1.5 million Americans with rheumatoid arthritis?
February 23, 2017
As Congress continues to debate the future of the Affordable Care Act, a new advocacy group has a message for key legislators: protect cystic fibrosis patients as you reshape health care policy.
February 21, 2017
The Institute for Clinical and Economic Review’s newest cost-effectiveness report underscores just how far economic modeling sometimes diverges from patients’ reality, explained the Institute for Patient Access in a February 17 letter. The report analyzes rheumatoid arthritis treatments’ value by modeling expenses for simulated patients over a lifetime on certain treatments.
February 17, 2017
Access to medication has become an all-too-common challenge for patients with one of the country’s most common diseases: diabetes.
February 9, 2017
New data on PCSK9 inhibitors is in – and it may bolster patients’ demands for the breakthrough cholesterol drugs in the face of health plan coverage barriers.
February 7, 2017
Chronic migraine is seldom a lone condition, explains a new white paper from the Headache & Migraine Policy Forum.
